| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $1.6M | +57.1% | +82.0% |
| SG&A Expense | $2.4M | +111.0% | +98.2% |
| Operating Income | -$4.1M | -85.5% | -91.4% |
| Net Income | -$4.1M | -86.7% | -92.6% |
| EPS (Basic) | -$0.30 | -76.5% | +3.2% |
| EPS (Diluted) | -$0.30 | -76.5% | +3.2% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $7.8M | -12.9% | -1.9% |
| Current Assets | $8.9M | -11.3% | +8.3% |
| Total Assets | $9.2M | -8.5% | +11.3% |
| Current Liabilities | $1.0M | +177.7% | +25.0% |
| Total Liabilities | $1.0M | +177.7% | +24.6% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$7.7M | — | — |
| Investing Cash Flow | -$300K | — | — |
| Financing Cash Flow | $8.8M | — | — |
| $8.2M |
| -15.5% |
| +9.8% |